Business Description
![Editas Medicine Inc Editas Medicine Inc logo](https://static.gurufocus.com/logos/0C0000B1VW.png?14)
Editas Medicine Inc
NAICS : 325412
SIC : 2834
ISIN : US28106W1036
Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.21 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -0.19 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -4.52 | |||||
Beneish M-Score | -1.48 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -12.8 | |||||
3-Year EBITDA Growth Rate | 1.3 | |||||
3-Year EPS without NRI Growth Rate | -0.7 | |||||
3-Year FCF Growth Rate | 17.3 | |||||
3-Year Book Growth Rate | -12.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | -8.41 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 44.6 | |||||
9-Day RSI | 39.64 | |||||
14-Day RSI | 39.24 | |||||
6-1 Month Momentum % | -28.23 | |||||
12-1 Month Momentum % | -36.75 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.85 | |||||
Quick Ratio | 3.85 | |||||
Cash Ratio | 3.76 | |||||
Days Sales Outstanding | 16.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.3 | |||||
Shareholder Yield % | -0.35 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -317.78 | |||||
Net Margin % | -288.59 | |||||
FCF Margin % | -255.91 | |||||
ROE % | -59.13 | |||||
ROA % | -40.8 | |||||
ROIC % | -133.25 | |||||
ROC (Joel Greenblatt) % | -457.77 | |||||
ROCE % | -51.86 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.73 | |||||
PB Ratio | 1.37 | |||||
Price-to-Tangible-Book | 1.37 | |||||
EV-to-EBIT | -0.37 | |||||
EV-to-EBITDA | -0.38 | |||||
EV-to-Revenue | 1.18 | |||||
EV-to-Forward-Revenue | 4.95 | |||||
EV-to-FCF | -0.46 | |||||
Price-to-Net-Current-Asset-Value | 2.39 | |||||
Price-to-Net-Cash | 2.53 | |||||
Earnings Yield (Greenblatt) % | -270.27 | |||||
FCF Yield % | -53.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Editas Medicine Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 67.033 | ||
EPS (TTM) ($) | -2.36 | ||
Beta | 0.96 | ||
Volatility % | 98.3 | ||
14-Day RSI | 39.24 | ||
14-Day ATR ($) | 0.258707 | ||
20-Day SMA ($) | 4.373635 | ||
12-1 Month Momentum % | -36.75 | ||
52-Week Range ($) | 3.74 - 11.66 | ||
Shares Outstanding (Mil) | 82.48 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Editas Medicine Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Editas Medicine Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Editas Medicine Inc Frequently Asked Questions
What is Editas Medicine Inc(LTS:0IFK)'s stock price today?
The current price of LTS:0IFK is $3.94. The 52 week high of LTS:0IFK is $11.66 and 52 week low is $3.74.
When is next earnings date of Editas Medicine Inc(LTS:0IFK)?
The next earnings date of Editas Medicine Inc(LTS:0IFK) is 2024-11-01 Est..
Does Editas Medicine Inc(LTS:0IFK) pay dividends? If so, how much?
Editas Medicine Inc(LTS:0IFK) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |